Vivos Therapeutics, Inc.

NasdaqCM:VVOS Rapporto sulle azioni

Cap. di mercato: US$14.1m

Vivos Therapeutics Gestione

Gestione criteri di controllo 4/4

Vivos Therapeutics Il CEO è R. Huntsman, nominato in Sep2016, e ha un mandato di 8.17 anni. la retribuzione annua totale è $ 657.70K, composta da 70.5% di stipendio e 29.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.53% delle azioni della società, per un valore di $ 215.53K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.8 anni e 4.4 anni.

Informazioni chiave

R. Huntsman

Amministratore delegato

US$657.7k

Compenso totale

Percentuale dello stipendio del CEO70.5%
Mandato del CEO8.2yrs
Proprietà del CEO1.5%
Durata media del management2.8yrs
Durata media del Consiglio di amministrazione4.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Even With A 27% Surge, Cautious Investors Are Not Rewarding Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Performance Completely

Nov 12
Even With A 27% Surge, Cautious Investors Are Not Rewarding Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Performance Completely

Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story

Sep 10
Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story

It's Down 44% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Apr 25
It's Down 44% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Feb 02
It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Fewer Investors Than Expected Jumping On Vivos Therapeutics, Inc. (NASDAQ:VVOS)

Apr 18
Fewer Investors Than Expected Jumping On Vivos Therapeutics, Inc. (NASDAQ:VVOS)

Vivos Therapeutics again delays Q2 2022 results

Aug 23

Vivos Therapeutics signs exclusive distribution agreement with GM Instruments for US and Canada

Jun 29

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Analysts Are More Bearish Than They Used To Be

May 21
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Analysts Are More Bearish Than They Used To Be

Vivos Therapeutics: First Take After The Broad Market Sell-Off

Mar 06

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di R. Huntsman rispetto agli utili di Vivos Therapeutics?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

-US$13m

Jun 30 2024n/an/a

-US$12m

Mar 31 2024n/an/a

-US$16m

Dec 31 2023US$658kUS$463k

-US$14m

Sep 30 2023n/an/a

-US$15m

Jun 30 2023n/an/a

-US$19m

Mar 31 2023n/an/a

-US$20m

Dec 31 2022US$938kUS$385k

-US$24m

Sep 30 2022n/an/a

-US$25m

Jun 30 2022n/an/a

-US$25m

Mar 31 2022n/an/a

-US$22m

Dec 31 2021US$1mUS$344k

-US$20m

Sep 30 2021n/an/a

-US$24m

Jun 30 2021n/an/a

-US$21m

Mar 31 2021n/an/a

-US$19m

Dec 31 2020US$455kUS$252k

-US$18m

Sep 30 2020n/an/a

-US$9m

Jun 30 2020n/an/a

-US$11m

Mar 31 2020n/an/a

-US$12m

Dec 31 2019US$328kUS$249k

-US$12m

Dec 31 2018US$284kUS$249k

-US$9m

Compensazione vs Mercato: La retribuzione totale di R. ($USD 657.70K ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 650.80K ).

Compensazione vs guadagni: La retribuzione di R. è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

R. Huntsman (66 yo)

8.2yrs

Mandato

US$657,701

Compensazione

Mr. R. Kirk Hunstman is the Co-Founder of Vivos Therapeutics, Inc. since September 2016 and has been its Chief Executive Officer and Director since September 2016 and has been its Chairman of the Board sin...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
R. Huntsman
Co-Founder8.2yrsUS$657.70k1.53%
$ 215.5k
Bradford Amman
CFO, Treasurer & Secretary6.1yrsUS$400.04k0.0017%
$ 236.2
Todd Huntsman
Co-Founder & Senior VP of Product and Technologyless than a yearNessun datoNessun dato
RaeAnn Byrnes
Co-Founder and Senior VP of Events & Clinical Advisory Servicesno dataNessun datoNessun dato
Susan McCullough
Co-Founder & Executive VP of Operationsless than a yearNessun datoNessun dato
Nicholas DeGennaro
Senior Vice President of Medical Integration Division5.1yrsNessun datoNessun dato
Ruth Hembree
Senior Vice President of Practice Servicesno dataNessun datoNessun dato
Stephanie Huebner
Senior Vice President of Dental Service Integration2.8yrsNessun datoNessun dato
John Ballard
Senior Vice President of Technologyless than a yearNessun datoNessun dato

2.8yrs

Durata media

Gestione esperta: Il team dirigenziale di VVOS è considerato esperto (durata media dell'incarico 2.8 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
R. Huntsman
Co-Founder8.2yrsUS$657.70k1.53%
$ 215.5k
Leonard Sokolow
Independent Director4.4yrsUS$63.00k0.0084%
$ 1.2k
Anja Krammer
Independent Director4.4yrsUS$58.00k0%
$ 0
Mark Lindsay
Independent Director4.4yrsUS$58.00k0%
$ 0
Matthew Thompson
Independent Director4.4yrsUS$63.00k0%
$ 0
Edward Zuckerberg
Member of Medical & Clinical Advisory Board3.8yrsNessun datoNessun dato
Ralph Green
Independent Director4.4yrsUS$58.00k0%
$ 0
Michael Gelb
Member of Medical & Clinical Advisory Board3.8yrsNessun datoNessun dato
Manisha Witmans
Member of Medical & Clinical Advisory Board3.8yrsNessun datoNessun dato
Tammarie Heit
Member of Medical & Clinical Advisory Board3.8yrsNessun datoNessun dato
Clete Kushida
Co-Chair of Medical & Clinical Advisory Board3.8yrsNessun datoNessun dato
Cecilia Wu
Co-Chair of Medical & Clinical Advisory Boardno dataNessun datoNessun dato

4.4yrs

Durata media

64yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di VVOS sono considerati esperti (durata media dell'incarico 4.4 anni).